Dutch vaccine developer Intravacc becomes public shareholding company effective from 1st January 2021
Dutch vaccine developer Intravacc becomes public shareholding company effective 1st January 2021 Bilthoven, The Netherlands, 22 December 2020 – Intravacc, one of the leading translational research and development vaccine institutes with an extensive track record in developing infectious diseases vaccines, today announced that it will become a Public Shareholding Company with limited liability (B.V.) as…